All Updates

All Updates

icon
Filter
Partnerships
Spruce Biosciences and HMNC partner to develop personalized medicine for major depressive disorder
Precision Medicine
Jun 4, 2024
This week:
M&A
Funding
TravelPerk raises USD 135 million in debt funding for expansion; acquires AmTrav
Travel Tech
Yesterday
Product updates
Apple announces Apple Pay Later shutdown
Buy Now, Pay Later
Jun 17, 2024
Management news
Velo3D appoints Brad Kreger as permanent CEO
Additive Manufacturing
Jun 17, 2024
Partnerships
Perplexity partners with SoftBank for AI search engine promotion in Japan
Generative AI Applications
Jun 17, 2024
Product updates
Runway launches Gen-3 Alpha for generating video clips
Generative AI Applications
Jun 17, 2024
Product updates
Adobe integrates Firefly into Acrobat with chat support across multiple documents in Acrobat AI Assistant
Generative AI Applications
Jun 17, 2024
Funding
Amplify Life raises USD 20 million in Series B to expand product suite
InsurTech: Personal Lines
Jun 17, 2024
Funding
Tinybird raises USD 30 million in Series B funding to improve real-time data analytics platform
Data Infrastructure & Analytics
Jun 17, 2024
Partnerships
The EVERY Company collaborates with Grupo Palacios to develop hen-less omelets
Plant-based Dairy & Egg
Jun 17, 2024
Partnerships
Believer Meats partners with AGWA to propel cultivated meat industry in MENA region
Cell-cultured Meat
Jun 17, 2024
Precision Medicine

Precision Medicine

Jun 4, 2024

Spruce Biosciences and HMNC partner to develop personalized medicine for major depressive disorder

Partnerships

  • Spruce Biosciences and HMNC Brain Health have entered a partnership to advance the development of Spruce's drug candidate, tildacerfontis, using HMNC's companion diagnostic tool for the treatment of major depressive disorder (MDD).

  • According to the agreement, HMNC will finance and manage a Phase II study of tildacerfont, in which the Cortibon tool will facilitate patient selection. Should the study yield favorable results, Spruce will have the option to secure exclusive worldwide rights to Cortibon. 

  • Spruce states that the collaboration could potentially impact up to 50% of MDD patients globally by replacing the traditional trial-and-error treatment approach, enhancing treatment effectiveness and lowering costs.

  • Spruce Biosciences is a late-stage biopharmaceutical company developing novel therapies for rare endocrine and neurological disorders. The company’s lead product candidate is tildacerfont, which is currently in trial for adult classic congenital adrenal hyperplasia, pediatric classic congenital adrenal hyperplasia, and polycystic ovary syndrome.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.